Aspen collaborates with India's SII on vaccines for Africa

1 September 2022

South Africa’s largest drugmaker Aspen Pharmacare (JSE: APN) closed up more than 5% at 14,750 rand yesterday, after it announced that one of its wholly-owned South African subsidiaries, Aspen SA Operations, has concluded a 10-year agreement with Serum Institute of India (SII) for Aspen SA Operations to manufacture, market and distribute four Aspen-branded routine vaccines in Africa, excluding certain markets due to the Serum Institute having grated prior rights to third parties.

The terms of agreement for the vaccines, namely pneumococcal, rotavirus, polyvalent meningococcal and hexavalent (“the Products”), include a technical transfer and formulation, fill and finish arrangement which grants Aspen SA Operations the rights to:

manufacture the products from bulk drug substance supplied by the Serum Institute; and
make available the products to markets in Africa by means of transactions with designated multilateral organizations, national governments of member states of the African Union (AU), and other public and private market customers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK